Paratek Pharmaceuticals Inc (PRTK.OQ)
PRTK.OQ on NASDAQ Stock Exchange Global Market
10.65USD
21 Aug 2018
10.65USD
21 Aug 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$10.65
$10.65
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
107,701
107,701
52-wk High
$29.00
$29.00
52-wk Low
$9.40
$9.40
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Buy | -0.87 | December | 22 Aug 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 6 | 6 | 6 | 6 |
| (2) OUTPERFORM | 4 | 4 | 4 | 4 |
| (3) HOLD | 0 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.40 | 1.40 | 1.40 | 1.40 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 9 | 2.70 | 12.00 | 0.00 | 6.00 |
| Quarter Ending Dec-18 | 9 | 12.12 | 69.50 | 0.00 | 1.85 |
| Year Ending Dec-18 | 10 | 15.09 | 69.80 | 0.05 | 17.06 |
| Year Ending Dec-19 | 10 | 42.79 | 185.30 | 12.90 | 52.72 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 8 | -0.87 | -0.55 | -1.05 | -0.75 |
| Quarter Ending Dec-18 | 8 | -0.68 | 1.11 | -1.09 | -0.81 |
| Year Ending Dec-18 | 9 | -3.41 | -1.69 | -3.91 | -3.15 |
| Year Ending Dec-19 | 9 | -3.04 | -0.07 | -4.11 | -2.22 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Jun-18 | 0.04 | 0.04 | 0.00 | 6.67 |
| Quarter Ending Mar-18 | 0.00 | 0.01 | 0.01 | 488.24 |
| Quarter Ending Dec-17 | 3.12 | 5.07 | 1.95 | 62.30 |
| Quarter Ending Sep-17 | 0.55 | 0.01 | 0.54 | 97.82 |
| Quarter Ending Jun-17 | 2.89 | 7.51 | 4.63 | 160.23 |
| Earnings (per share) | ||||
| Quarter Ending Jun-18 | -0.93 | -0.94 | 0.01 | -1.48 |
| Quarter Ending Mar-18 | -0.90 | -0.91 | 0.01 | -0.55 |
| Quarter Ending Dec-17 | -0.75 | -0.78 | 0.03 | -4.35 |
| Quarter Ending Sep-17 | -0.94 | -0.77 | 0.17 | -18.09 |
| Quarter Ending Jun-17 | -0.95 | -0.66 | 0.29 | -30.89 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 2.70 | 2.70 | 3.04 | 3.04 | 6.00 |
| Quarter Ending Dec-18 | 12.12 | 12.12 | 12.02 | 12.02 | 1.85 |
| Year Ending Dec-18 | 15.09 | 15.09 | 15.31 | 15.31 | 17.06 |
| Year Ending Dec-19 | 42.79 | 42.79 | 44.88 | 44.88 | 52.72 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | -0.87 | -0.87 | -0.85 | -0.85 | -0.75 |
| Quarter Ending Dec-18 | -0.68 | -0.68 | -0.67 | -0.67 | -0.81 |
| Year Ending Dec-18 | -3.41 | -3.41 | -3.36 | -3.36 | -3.15 |
| Year Ending Dec-19 | -3.04 | -3.04 | -3.01 | -3.11 | -2.22 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-18 | 0 | 0 | 4 | 2 |
| Year Ending Dec-19 | 0 | 0 | 0 | 4 |
| Earnings | ||||
| Quarter Ending Sep-18 | 0 | 0 | 3 | 2 |
| Quarter Ending Dec-18 | 0 | 0 | 5 | 1 |
| Year Ending Dec-18 | 0 | 0 | 4 | 3 |
| Year Ending Dec-19 | 0 | 0 | 2 | 5 |
Earnings vs. 
Estimates- UPDATE 1-U.S. FDA panel backs approval of Paratek's antibiotic
- U.S. FDA panel backs approval of Paratek's antibiotic
- UPDATE 1-Paratek antibiotic not inferior to current treatments-FDA staff
- Paratek antibiotic not inferior to current treatments-FDA staff
- BRIEF-Paratek Pharmaceuticals Reports Q1 Loss Per Share $0.91